Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
2
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
0 competitors in Breast Cancer, Early Breast Cancer
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Etcamah
Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor (for biomarker based patient-selection, see section 4.2 and 5.1).
View on EMAHypercholesterolemia
Healthy Japanese Children Age 2 Years Through 6 Years
Generalized Anxiety Disorder
Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer